Section Arrow
NRIX.NASDAQ
- Nurix Therapeutics
Quotes are at least 15-min delayed:2025/12/26 00:12 EST
Regular Hours
Last
 19.36
+0.07 (+0.36%)
Day High 
19.84 
Prev. Close
19.29 
1-M High
22.4999 
Volume 
480.46K 
Bid
18.75
Ask
19.62
Day Low
19.21 
Open
19.47 
1-M Low
16.02 
Market Cap 
1.96B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 18.9 
20-SMA 18.4 
50-SMA 14.71 
52-W High 22.4999 
52-W Low 8.18 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.97/-3.61
Enterprise Value
1.98B
Balance Sheet
Book Value Per Share
3.67
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
54.55M
Operating Revenue Per Share
0.68
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
APLTApplied Therapeutics0.1154-0.0003-0.26%-- 
INDPIndaptus Therapeutics Inc2.65+0.7+35.90%-- 
OMEROmeros Corp15.36+6.61+75.54%-- 
DRMADermata Therapeutics Inc2.37+0.33+16.18%0.13PE
CTXRCitius Pharmaceuticals Inc0.8006-0.2394-23.02%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.